TITLE

Thrombolytic Therapy -- Indications, Advantages and Disadvantages

AUTHOR(S)
Forbes, Charles D.; Lowe, Gordon D. O.; Prentice, Colin R. M.
PUB. DATE
November 1978
SOURCE
Angiology;Nov1978, Vol. 29 Issue 11, p783
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The purpose of this article is to examine the available evidence for activators in thrombotic state and to balance the potential hazards of therapy against the possible benefit. The authors in this article state that there seems little doubt that the natural fibrinolytic process performs an important physiologic role in regulating the removal of fibrin laid down on vascular endothelium. In thrombotic states the use of activators of this system has great theoretical attraction, and for 25 years such an agent (streptokinase) has been available for therapeutic use. But there is still little clinical agreement on its use or the use of similar agents.
ACCESSION #
16395326

 

Related Articles

  • Fibrin Binding and the Regulation of Plasminogen Activators during Thrombolytic Therapy. Longstaff, C.; Williams, S.; Thelwell, C. // Cardiovascular & Hematological Agents in Medicinal Chemistry;2008, Vol. 6 Issue 3, p212 

    First generation thrombolytics (streptokinase and urokinase) had no fibrin binding capabilities and caused systemic plasminogen activation with concomitant destruction of haemostatic proteins. A primary driving force behind the development of the second generation plasminogen activator tissue...

  • Streptokinase as Fibrinolytic Agent. Hamid, Mohsina; Khalil-Ur-Rehman; Asghar, Muhammad; Sarwar, Muhammad // Asian Journal of Chemistry;2012, Vol. 24 Issue 4, p1809 

    Accumulation of fibrin in the blood vessels usually results in the thrombosis, leading to myocardial infarction and other cardiovascular diseases. For thrombolytic therapy microbial fibrinolytic enzymes have now attracted much more attention than typical thrombolytic agents because of the high...

  • EXPERIENCE WITH FIBRINOLYTIC THERAPY OF VASCULAR OCCLUSIVE DISEASE. Warner, W. L. // Vascular Surgery;Nov/Dec1977, Vol. 11 Issue 6, p364 

    1. There may well be a place for streptokinase therapy in selected patients with chronic arterial occlusion, but the emphasis should be on developing information on selection criteria. 2. Efficacy and safety have been established for the use of streptokinase in occluded AV cannulae, but this may...

  • THROMBOLYTIC THERAPY: DIFFERENCES BETWEEN STREPTOKINASE AND UROKINASE. Bell, William R. // Vascular Surgery;Nov/Dec1977, Vol. 11 Issue 6, p378 

    Compares the relative potency of streptokinase and urokinase as agents for thrombolytic therapy in patients with pulmonary emboli. Therapeutic regimens of streptokinase and urokinase; Biochemical properties of streptokinase and urokinase; Assessment of the therapeutic improvement after the...

  • THROMBOLYTIC ACTIVITY OF CENTELLA ASIATICA LEAVES. Rishikesh; Ghosh, Drishti Rani; Rahman, Moshfiqur // International Journal of Pharmacy;2013, Vol. 3 Issue 2, p308 

    The methanol extract of Centella asiatica was estimated for thrombolytic effect. The extract demonstrated moderate thrombolytic activity which was 25.01 % where as the thrombolytic activity of standard was found 88.23 %. Thrombolytic indicates that have potent clot lysis property and...

  • Development of New Fibrinolytic Agents. Ueshima, Shigeru; Matsuo, Osamu // Current Pharmaceutical Design;Mar2006, Vol. 12 Issue 7, p849 

    Since the activation of coagulation system and platelets triggers the thrombosis, the agents possessing anticoagulation or anti-platelet function have been used for the antithrombotic procession actions. However, in the physiological condition, the fibrinolytic system serves as antithrombotic,...

  • THROMBOLYSIS FOR ACUTE BUDD-CHIARI SYNDROME: CASE REPORT AND LITERATURE REVIEW. Raju, G. S.; Felver, M.; Olin, J. W.; Satti, S. D. // American Journal of Gastroenterology;Jun1996, Vol. 91 Issue 6, p1262 

    Presents a case report on the role of thrombolysis in acute Budd-Chiari syndrome. Medical history of the patuent with acute Budd-Chiari syndrome; Other agents aside from streptokinase used in acute Budd-Chiari syndrome; Complications from using thrombolytic agents.

  • COMBINED THROMBECTOMY AND ISOLATED LIMB PERFUSION WITH STREPTOKINASE IN THE TREATMENT OF DEEP VENOUS THROMBOSIS. Nachbur, Bernard // Vascular Surgery;Nov/Dec1977, Vol. 11 Issue 6, p395 

    A new mode of treatment for extensive acute and subacute deep venous thrombosis of the lower extremities combines the beneficial effects of surgical thrombectomy and of thrombolysis with streptokinase during the course of a single surgical intervention. Rapid-flow regional perfusion is the...

  • Correction.  // American Journal of Health-System Pharmacy;7/15/2014, Vol. 71 Issue 14, p1157 

    A correction to the article "Use of Argatroban and Catherter-directed Thrombolysis with Altephase in an Oncology Patient with Heparin-induced Thrombocytopenia with Thrombosis," in the May 1, 2014 issue is presented.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics